Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Psychiatr Res ; 130: 321-326, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32877825

RESUMO

BACKGROUND: Psychomotor Retardation is a key symptom of Major Depressive Disorder. According to the literature its presence may affect the prognosis of treatment. Aim of the present study is to investigate the prognostic role of Psychomotor Retardation in patients with unipolar Psychotic Depression who are under antidepressant treatment. METHODS: The Salpetriere Retardation Rating Scale was administered at baseline and after 6 weeks to 122 patients with unipolar Psychotic Depression who were randomly allocated to treatment with imipramine, venlafaxine or venlafaxine plus quetiapine. We studied the effects of Psychomotor Retardation on both depression and psychosis related outcome measures. RESULTS: 73% of the patients had Psychomotor Retardation at baseline against 35% after six weeks of treatment. The presence of Psychomotor Retardation predicted lower depression remission rates in addition to a higher persistence of delusions. After six weeks of treatment, venlafaxine was associated with higher levels of Psychomotor Retardation compared to imipramine and venlafaxine plus quetiapine. CONCLUSIONS: Our data confirm that Psychomotor Retardation is a severity marker of unipolar Psychotic Depression. It is highly prevalent and predicts lower effectivity of antidepressant psychopharmacological treatment.


Assuntos
Transtorno Depressivo Maior , Transtornos Psicóticos , Antidepressivos/uso terapêutico , Depressão , Transtorno Depressivo Maior/tratamento farmacológico , Humanos , Prognóstico , Transtornos Psicóticos/complicações , Transtornos Psicóticos/tratamento farmacológico , Resultado do Tratamento , Cloridrato de Venlafaxina/uso terapêutico
2.
Psychiatry Res ; 207(1-2): 100-6, 2013 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-23167986

RESUMO

Research suggests that individuals with binge eating pathology (e.g., bulimia nervosa (BN) and binge eating disorders (BED)) have decision making impairments and particularly act impulsively in response to negative affect. The aim of this study was to examine the influence of negative affect on choice behavior in women with BN and BED. Ninety women (59 with BN or BED and 31 healthy controls) watched a sad or control film fragment and were subsequently asked to complete a choice behavior task (as measured by a variation of the Bechara Gambling Task (BGT)). Results showed that negative affect influenced choice behavior differently in healthy controls and in women with BN and BED after punishment (but not after reward). In the context of increased negative affect, punishment was associated with more disadvantageous choice behavior in both BN and BED women but not in healthy controls, while the effect was the exact opposite in both groups after a decrease in negative affect. Levels of sadness were not found to influence choice behavior after reward in either groups. These findings suggest that emotional states may have a direct impact on choice behavior of individuals with binge eating pathology and are not only related to pathological behavior itself.


Assuntos
Bulimia/complicações , Bulimia/psicologia , Comportamento de Escolha/fisiologia , Transtornos Cognitivos/etiologia , Emoções , Punição/psicologia , Adulto , Análise de Variância , Bulimia/classificação , Feminino , Jogos Experimentais , Humanos , Comportamento Impulsivo/etiologia , Testes de Personalidade , Estimulação Luminosa , Escalas de Graduação Psiquiátrica , Adulto Jovem
3.
J Affect Disord ; 123(1-3): 238-42, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19880189

RESUMO

BACKGROUND: Data about follow-up after acute pharmacological treatment of psychotic depression are scarce. METHODS: A 4 month open follow-up was done, preferentially with same medication as during acute treatment, of patients (n=59) with DSM-IV-TR major depressive disorder with psychotic features, aged 18 to 65 years, who had completed as responders an acute double-blind 7 week trial with imipramine, venlafaxine or venlafaxine plus quetiapine. Main outcome measures were Hamilton Rating Scale for Depression and Clinical Global Impression Scale. RESULTS: Six patients dropped out during the 4 month follow-up. Almost all patients (86.4%; 51/59) remained responder while remission rate increased from 59.3% (35/59) to 86.8% (46/53), independent of treatment. Relapse rate was low (3.8%; 2/53). Tolerability was good. Weight increased with all treatments. LIMITATIONS: Limitations were the limited sample size and consequent limited statistical power. The treatment during follow-up was not double-blind. CONCLUSIONS: Continuation treatment with the same medication that was effective in the acute treatment trial, remained effective during the 4 month follow-up in many patients leading to further improvement, and was well tolerated.


Assuntos
Transtornos Psicóticos Afetivos/tratamento farmacológico , Antidepressivos/uso terapêutico , Antipsicóticos/uso terapêutico , Cicloexanóis/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Dibenzotiazepinas/uso terapêutico , Imipramina/uso terapêutico , Adulto , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Países Baixos , Fumarato de Quetiapina , Resultado do Tratamento , Cloridrato de Venlafaxina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA